McKesson Corporation $MCK Shares Acquired by Y Intercept Hong Kong Ltd

Posted by George Bondi on Jul 3rd, 2026

Y Intercept Hong Kong Ltd increased its stake in McKesson Corporation (NYSE:MCK – Free Report) by 3,836.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,652 shares of the company’s stock after purchasing an additional 16,229 shares during the period. Y Intercept Hong Kong Ltd’s holdings in McKesson were worth $14,410,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in MCK. Fjarde AP Fonden Fourth Swedish National Pension Fund grew its stake in McKesson by 38.7% during the 1st quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 77,237 shares of the company’s stock worth $66,838,000 after buying an additional 21,544 shares during the last quarter. Elevation Point Wealth Partners LLC lifted its stake in McKesson by 236.8% in the first quarter. Elevation Point Wealth Partners LLC now owns 3,550 shares of the company’s stock valued at $3,074,000 after buying an additional 2,496 shares during the last quarter. Sound Income Strategies LLC lifted its stake in McKesson by 33.9% in the first quarter. Sound Income Strategies LLC now owns 162 shares of the company’s stock valued at $141,000 after buying an additional 41 shares during the last quarter. Patten Group Inc. acquired a new position in shares of McKesson during the first quarter valued at $201,000. Finally, Keybank National Association OH boosted its holdings in shares of McKesson by 1.9% during the first quarter. Keybank National Association OH now owns 4,323 shares of the company’s stock valued at $3,741,000 after acquiring an additional 81 shares during the period. Institutional investors and hedge funds own 85.07% of the company’s stock.

Insider Activity at McKesson

In related news, EVP Michele Lau sold 3,550 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $761.09, for a total transaction of $2,701,869.50. Following the transaction, the executive vice president owned 3,247 shares in the company, valued at $2,471,259.23. This trade represents a 52.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Thomas L. Rodgers sold 699 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $735.27, for a total value of $513,953.73. Following the sale, the executive vice president directly owned 2,268 shares in the company, valued at approximately $1,667,592.36. The trade was a 23.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 20,285 shares of company stock valued at $15,546,137. 0.06% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Citigroup dropped their price objective on shares of McKesson from $975.00 to $945.00 and set a “buy” rating on the stock in a report on Thursday, May 14th. Barclays reduced their target price on shares of McKesson from $1,050.00 to $925.00 and set an “overweight” rating for the company in a research note on Wednesday, June 10th. Leerink Partners restated an “outperform” rating and issued a $1,085.00 target price on shares of McKesson in a research report on Thursday, March 5th. Wall Street Zen lowered shares of McKesson from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $875.00 price target on shares of McKesson in a report on Friday, May 8th. Fourteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, McKesson has a consensus rating of “Moderate Buy” and an average target price of $960.53.

Get Our Latest Analysis on MCK

McKesson Stock Performance

Shares of MCK opened at $786.17 on Friday. McKesson Corporation has a one year low of $637.00 and a one year high of $999.00. The stock’s fifty day moving average is $770.09 and its 200-day moving average is $839.35. The firm has a market capitalization of $92.05 billion, a price-to-earnings ratio of 20.44, a price-to-earnings-growth ratio of 1.26 and a beta of 0.31.

McKesson (NYSE:MCK – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported $11.69 earnings per share for the quarter, topping the consensus estimate of $11.56 by $0.13. The business had revenue of $96.30 billion during the quarter, compared to the consensus estimate of $101.35 billion. McKesson had a net margin of 1.18% and a negative return on equity of 345.35%. The company’s quarterly revenue was up 6.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $10.12 earnings per share. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. Analysts forecast that McKesson Corporation will post 44.28 EPS for the current fiscal year.

McKesson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, July 1st. Shareholders of record on Monday, June 1st were given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date was Monday, June 1st. McKesson’s payout ratio is 8.53%.

McKesson Company Profile

(Free Report)

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.